1999³â 11¿ù
|
ȸ»ç ¼³¸³
|
2000³â 4¿ù
|
Çѱ¹»ý¸í°øÇבּ¸¿ø ¹ÙÀÌ¿Àº¥Ã³¼¾Å¸ ÀÔÁÖ
|
2000³â 6¿ù
|
º¥Ã³±â¾÷ÀÎÁõ
|
2000³â 10¿ù
|
¹«Çѱâ¼úÅõÀÚ,
SK, SKC, »ï¾ç»ç·ÎºÎÅÍ ÅõÀÚÀ¯Ä¡
|
2000³â 11¿ù
|
(ÁÖ)ÇÁ¶óÀÓ¹ÙÀÌ¿À ÇÕº´
|
2000³â 12¿ù
|
»ý¹°¼ÒÀ翬±¸¼Ò ¹× À¯Àüü¿¬±¸¼Ò¸¦ °úÇбâ¼úºÎ·ÎºÎÅÍ
±â¾÷ºÎ¼³ ¿¬±¸¼Ò ÀÎÁõ
|
2001³â 3¿ù
|
µ¶ÀϹٽºÇÁ(ÁÖ)¿¡ ¡®¾²·¹¿À´Ñ¡¯ »ý»ê±â¼ú ÀÌÀü
|
2001³â 5¿ù
|
ÀϺ» µ¿°æ»ç¹«¼Ò °³¼³
|
2001³â 7¿ù
|
´ë»ó»ç·á(ÁÖ)¿Í Á¦Ç° °øµ¿°³¹ß Çù¾à ¹× ÀϺ» OSAKA ´ëÇÐ °øµ¿¿¬±¸
°è¾à ü°á
|
2001³â 7¿ù
|
ISO 9001ÀÎÁõ
|
2001³â 10¿ù
|
°úÇбâ¼úºÎ, º¸°Çº¹ÁöºÎ,
¿øÀڷº´¿ø°ú ¹ÙÀÌ¿À¾Ë¾ØÁî Ç׾ϸ鿪Áõ°Á¦ Áø»ê °³¹ß °øµ¿ ¹ßÇ¥ (KBS 9½Ã´º½º, SBS ±â¾÷Æ÷Ä¿½º, SBS »ý¹æ¼Û Today, MBC ½Ã»ç¸Å°ÅÁø 2580 º¸µµ)
|
2001³â 11¿ù
|
µ¶ÀÏ ·¹°Õ½ººÎ¸£Å© »ç¹«¼Ò °³¼³
|
2001³â 12¿ù
|
(ÁÖ) »õÇÑÁ¦¾à°ú DEOMASTER-DCX ±â¼úÀÌÀü
|
2002³â 6¿ù
|
¼¿ï°æÁ¦½Å¹® 2002 »ý¸í°øÇÐ ±â¼úÇõ½Å ¿ì¼ö±â¾÷ ¼±Á¤
|
2002³â 10¿ù
|
º´¿ªÆ¯·Ê¾÷ü ÁöÁ¤
|
2002³â 10¿ù
|
¹Ì±¹ »ç¹«¼Ò °³¼³
|
2002³â 11¿ù
|
¹Ì±¹ VSÁ¦¾à°ú Ç÷Àü¿ëÇØÈ¿¼Ò ³´ÅäÅ°³ªÁ¦ µ¶Á¡°ø±Þ°è¾à ü°á
|
2003³â 1¿ù
|
½ºÀ§½º ·çÄ¡´Ï Á¦¾à°ú ÇÇÀÓ¾à ±â¼úÀÌÀü ¹× µ¶Á¡ÆǸŠ°è¾à
|
2003³â 6¿ù
|
¹Ì±¹ VSÁ¦¾àÀ» ÅëÇÏ¿© ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ ³´ÅäÅ°³ªÁ¦ Ãâ½Ã ½ÃÆÇ
|
2003³â 7¿ù
|
°¡¿ìµðȯ°æ À½½Ä¹° ¼Ò¸ê ¹Ì»ý¹° ±â¼ú ÀÌÀü
|
2003³â 11¿ù
|
¹Ì±¹ FDA ¹ÙÀÌ¿À¾Ë¾ØÁî ³ªÅäÅ°³ªÁ¦°¡ Functional Food·Î µîÀçµÊ
|
2003³â 12¿ù
|
Â÷¼¼´ë ÇÙ½Éȯ°æ±â¼ú°³¹ß»ç¾÷ ÃÖÁ¾ Æò°¡ ¼º°ø Å뺸(Çѱ¹È¯°æ±â¼úÁøÈï¿ø)
|
2004³â 2¿ù
|
°ñ°üÀý¿° Ä¡·áÁ¦ SAMe ½ÅdzÁ¦¾à ±â¼úÀÌÀü
|
2004³â 3¿ù
|
Human Placenta ÁÖ»çÁ¦ ±â¼úÀÌÀü ¹× µ¶Á¡ÆǸÅ
°è¾à (Human Placenta´Â WHO¿¡¼
°øÀÎÇÑ ½ÃÇè±â°üÀÎ IRI¿¡¼ ¹ÙÀÌ·¯½º ºÒÈ°È °øÀÎ ÀÎÁõ)
|
2004³â 3¿ù
|
Áß±¹ ±¤µ¿¼º National Health Technology
Park ¿¬±¸¼Ò¿¡ Human Placenta ÁÖ»çÁ¦ Á¦Á¶ ±â¼úÀÌÀü
|
2004³â 3¿ù
|
(ÁÖ)ÀϺ» ³´ÅäÆйи®
³ªÅäÅ°³ªÁ¦ µ¶Á¡ °ø±Þ °è¾à ü°á
|
2004³â 10¿ù
|
µ¿´öÁ¦¾à "ÀÎÅÂ¹Ý ÁÖ»çÁ¦(Placenta Injection)" ±â¼ú ÀÌÀü ¹× µ¶Á¡ °ø±Þ °è¾à
|
2005³â 2¿ù
|
¹Ì±¹ Ä÷³ºñ¾Æ ´ëÇÐ Robert L. Fine±³¼ö¿Í International Journal of Oncology¿¡
'BRD-glucan exhibits potent immunochemotherapeutic activity' ³í¹® °øµ¿
¹ßÇ¥
|
2005³â 5¿ù
|
'Human Placenta LucchiniÀÇ ¼Õ»óµÈ ô¼ö¿¡¼ÀÇ
ÀÛ¿ë±âÀü'À» ¼¿ï¾Æ»êÁß¾Óº´¿ø°ú °øµ¿¿¬±¸
|
2005³â 9¿ù
|
Áß±¹ S.H.Á¦¾à À¯ÇÑ°ø»ç¿Í ŹÝÁÖ»çÁ¦ Á¦Á¶ ±â¼úÀÌÀü ÁöºÐ 50% º¸À¯
|
2005³â 10¿ù
|
½ºÀ§½º Mergens S. A. ¿Í ģȯ°æ ¸ð±â¾à FXB-R ¿Ü 5Ç°¸ñ µ¶Á¡°ø±Þ °è¾à ü°á
|
2006³â 4¿ù
|
Á¦39ȸ ¡°°úÇÐÀÇ ³¯¡± ÃÖ¹®¼ö ´ëÇ¥ÀÌ»ç ´ëÇѹα¹ °úÇбâ¼ú»ó
¼ö»ó
|
2006³â 7¿ù
|
¿Àâ°úÇлê¾÷´ÜÁö Áß¾Ó¿¬±¸¼Ò ¹× °øÀå ÁØ°ø(1,500Æò)
|
2006³â 8¿ù
|
2006 º¥Ã³±â¾÷´ë»ó ¼ö»ó
|
2010³â 2¿ù
|
¾¾¾ÖƲ WESTPORT¿Í
Zn ÃßÃâ °øµ¿°³¹ßÂø¼ö
|
2011³â 6¿ù
|
ÆDZ³Å×Å©³ëº§¸® »ç¿Á ÁØ°ø
|
2012³â 1¿ù
|
¿À¼Û»ý¸í°úÇдÜÁö °øÀå ÁØ°ø
|
2013³â 4¿ù
|
(ÁÖ)È´ÏÇÉÄÚ¸®¾Æ
ÈÀåÇ°¿ø·á °øµ¿°³¹ßÂø¼ö ÁöºÐ 15%ȹµæ
|
2014³â 1¿ù
|
¹Ì±¹ VESTAÁ¦¾à°ú ÇÕÀÛ VESTA INTERNATIONAL.LLC ¼³¸³
|